(Total Views: 513)
Posted On: 04/01/2020 6:07:37 AM
Post# of 154006
Quote:
The new protocol for Severely Ill COVID-19 patients is for 342 patients, double blinded with 2:1 ratio. Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 14 days.
Interesting. So a fairly large study which however should recruit and read-out very quickly given current circumstances...
(3)
(0)
